Launch Optimisation2019-11-12T12:08:50+00:00

Launch Optimisation

From new product launches to label extensions, our comprehensive launch optimisation expertise considers how all external environmental factors can be taken into account to make your launch plan more effective.

It is absolutely vital to understand how competitors will seek to impede your launch and shape your market, especially by influencing key stakeholders, to create an unfavourable launch environment. Deallus excels at integrating the external competitive environment into your plan to strengthen working assumptions and provide increased confidence for a clearer path forward.

Deallus Stakeholder segmentation and growth strategy

Stakeholder segmentation and growth strategy

Mapping and segmenting influential stakeholders affecting the brand

Deallus Registration requirements and timelines

Registration requirements and timelines

Understanding registrations and post registration requirements and possibilities

Deallus Launch engagement strategies

Launch engagement strategies

Developing sustained insights into the evolving dynamics of key launch markets, to ensure alignment between global and local launch strategies

Competitor analysis

Mapping the competitor landscape whilst assessing biosimilar and generic threats

Deallus Pricing strategy

Pricing strategy

Mapping and analysing competitor pricing strategies to ensure strong strategic decision makings

Find out more

Launch optimisation related insight

All Deallus Insight

The Future of JAK Inhibitors

Categories: White Paper|Tags: , , |

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. Yet despite the hurdles, JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted. Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option? In this white paper, we investigate the current state of JAKs and explore their likelihood of success in the future.

Launching for Success

Categories: Case Study|Tags: , , , |

Our client was a small-to medium-sized pharmaceutical company with a limited development pipeline who was in the process of launching their first product, an orphan drug, for treating a rare disease. They were a relatively small organisation with no prior knowledge of the competitive environment and no standardised launch planning process or procedures. This case study explores how our client engaged us to help them understand their competitive landscape, streamline launch efforts across markets, and stress test and revise their launch planning strategies.

The Three A’s of Launch Readiness

Categories: White Paper|Tags: , , , |

Drug launch failures happen more frequently than pharma companies care to admit. Anticipate, Adapt and Align - the three A’s of successful pharma launch strategy. To understand and implement them requires strategic vision, a holistic understanding of every vagary of the marketplace, and a forthright and ruthlessly honest assessment of both the product being launched and the competitive space it is meant to occupy.

Go to Top